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● Background: Vascular access surveillance by ultrasound dilution blood flow rate (Qa) measurement is widely
recommended; however, optimal criteria for detecting stenosis and predicting thrombosis in arteriovenous fistulae
(AVFs) are still not clearly defined. Methods: In a blinded trial, we evaluated the accuracy of single Qa measurement,
Qa adjusted for mean arterial pressure (Qa/MAP), and decrease in Qa over time (dQa) in detecting stenosis and
predicting thrombosis in an unselected population of 120 hemodialysis subjects with native forearm AVFs (91
AVFs, located at the wrist; 29 AVFs, located at the midforearm). All AVFs underwent fistulography, which identified
greater than 50% stenosis in 54 cases. Results: Receiver operating characteristic curve analysis showed that dQa,
Qa, and Qa/MAP have a high stenosis discriminative ability with similar areas under the curve (AUCs), ie, 0.961 
0.025, 0.946  0.021, and 0.912  0.032, respectively. In the population as a whole, optimal thresholds for stenosis
were Qa less than 750 mL/min alone and in combination with dQa greater than 25% (efficiency, 90%); however, the
best threshold depended on anastomotic site; it was Qa less than 750 mL/min for an AVF at the wrist and Qa less
than 1,000 mL/min for an AVF in the midforearm. Qa was the best predictor of incipient thrombosis (AUC, 0.981 
0.013) with an optimal threshold at less than 300 mL/min (efficiency, 94%). Pooled intra-assay and interassay
variation coefficients were 8.2% for MAP, 7.9% for Qa, and 11.2% for Qa/MAP. Conclusion: Our study shows that
ultrasound dilution Qa measurement is a reproducible and highly accurate tool for detecting stenosis and
predicting thrombosis in forearm AVFs. Neither Qa/MAP nor dQa improve the diagnostic performance of Qa alone,
although its combination with dQa increases the test’s sensitivity for stenosis. Am J Kidney Dis 42:331-341.
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NATIVE FOREARM arteriovenous fistulae(AVFs) are regarded as the first-choice
vascular access for hemodialysis because of their
superior patency rates and easier maintenance
after they have fully matured.1 However, even
mature AVFs are prone to dysfunction and fail-
ure, almost invariably caused by the onset of
stenosis. A number of studies have reported that
prophylactic stenosis correction prolongs the use-
ful life of the access, and routine surveillance for
the detection of hemodynamically significant ste-
nosis consequently has been recommended
widely to allow preemptive intervention before
thrombosis.1
Because the physiological effect of stenosis is
to decrease access blood flow rate (Qa), direct
access blood flow measurements are considered
the most useful surveillance method, and ultra-
sound dilution2 has became the most popular and
validated technique. A major problem of Qa
surveillance lies in its variability as a result of
major hemodynamic changes often observed dur-
ing and between dialysis sessions, making it
difficult to determine accurate cutoff values for
predicting access dysfunction and stenosis. In an
attempt to improve reproducibility, adjusting for
mean arterial pressure (MAP; Qa/MAP or MAP/
Qa, ie, access resistance)3-5 and percentage of
decrease in Qa over time (dQa),6 rather than
considering single Qa measurements, and measur-
ing Qa early in dialysis or always at the same
time7 have been recommended for monitoring
purposes.
Most experience of Qa monitoring has been
gained in grafts, and criteria for detecting dys-
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function are less well established in AVFs, al-
though the current opinion is that AVFs should
be monitored as outlined for grafts.1 However,
few studies have addressed the issue of the
ability of Qa measurement to detect stenosis in
AVFs.8-10 Two studies proposed a Qa cutoff value
less than 500 mL/min for diagnosing stenosis
based on predictive values of a positive test of
56%8 and 81%9; however, lack of a control group
with angiographic access evaluation makes it
impossible to truly evaluate predictive accuracy
(ie, to identify optimal sensitivity and specific-
ity). Another study that included grafts and a
small sample of AVFs, mostly at the elbow,
showed that criteria proposed by the National
Kidney Foundation-Dialysis Outcomes Quality
Initiative (K/DOQI) guidelines for referral for
fistulography (Qa  600 mL/min or Qa  1,000
mL/min with 25% decrease during 4 months)
ensured total sensitivity and 83% specificity for
stenosis.10 Unfortunately, results were reported
without distinguishing between AVFs and grafts.
Thus, applicability of these criteria to AVFs
alone is questionable. The investigators reported
that trend in Qa was a better predictor than
absolute Qa, a finding not confirmed by others,9
who favored single Qa measurements over dQa
in a series of mostly forearm AVFs. To our
knowledge, whether adjusting Qa for MAP im-
proves stenosis prediction in AVFs is unknown.
It also has been suggested that as an alterna-
tive to Qa, measuring access recirculation is of
potential benefit as a marker of stenosis in AVFs
because fistulae may still be patent at lower Qas
than the prescribed dialysis blood pump flow
rates (Qbs).1
Low Qa also has been associated with in-
creased risk for thrombosis and failure in AVFs,
and various criteria have been proposed for pre-
dicting incipient thrombosis, including single Qa
values ranging from less than 800 mL/min11-13 to
less than 300 mL/min14 or dQa greater than
20%.6 Results of most of these studies are diffi-
cult to interpret and reconcile, either because of
inadequate sample sizes6,12,15 or because they
report cumulative data for both AVFs and
grafts.6,11,12,15,16 However, even studies adequate
in sample size13,17 and considering AVFs
alone13,14,17 fail to provide more consistent data,
reporting threshold Qa values ranging from less
than 300 to 400 mL/min14,17 to less than 800
mL/min.13
The presence of anatomic stenosis detected by
duplex ultrasound or angiography reportedly is
more effective or at least as effective18,19 as Qa
surveillance in predicting graft thrombosis and/or
failure, but this is unlikely to apply to AVFs
because they can remain patent for a long time,
even at low Qas, which are usually the functional
outcome of stenosis. However, a comprehensive
analysis of the relationship between Qa, stenosis,
and thrombosis is lacking in AVFs and is essen-
tial to the determination of an optimal access
monitoring protocol.
The primary aim of our study is to evaluate the
diagnostic role of Qa measurement by ultrasound
dilution in detecting stenosis and predicting in-
cipient thrombosis in native mature forearm AVFs
in an unselected population of hemodialysis sub-
jects and to identify the best thresholds. Addi-
tional aims are to evaluate Qa measurement
reproducibility and compare its predictive ability
with surrogate Qa markers, such as measuring
access recirculation and monitoring dialysis Qb.
PATIENTS AND METHODS
This blinded study was performed in an unselected popu-
lation of hemodialysis subjects from 2 hemodialysis units at
the Ospedale Policlinico (unit A) and Ospedale Civile Mag-
giore (unit B) in Verona, Italy, between February 1998 and
December 2001.
All subjects gave their informed consent to the study
protocol, which was approved by the local ethical commit-
tee.
Study Design
Prediction of stenosis. One hundred twenty-seven preva-
lent hemodialysis subjects with native, mature, forearm,
radiocephalic AVFs were evaluated.
In February to April 1998, a total of 46 prevalent subjects
were enrolled from unit A. In January to May 2001, an
additional 45 eligible subjects from unit A and 36 subjects
from unit B were added to the study.
In the vast majority of subjects, the arteriovenous anasto-
mosis was located at the wrist, but in 29 subjects, it was
located in the midportion of the forearm, up to approxi-
mately 8 cm below the crease of the elbow either because of
a more distal AVF failing to mature (n  8) or electively
(because suitable distal arteries and superficial veins were
lacking as a consequence of arterial wall thickening caused
by atherosclerosis and/or calcification and repeated venipunc-
ture), according to the surgical team’s clinical judgment.
All AVFs were evaluated by Qb monitoring, Qa measure-
ment by ultrasound dilution, and access recirculation mea-
sured by urea-based (Ru) and ultrasound dilution (Rhd)
methods.
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Tests under investigation and reference standard were
evaluated separately; the former were performed 1 to 3
weeks before fistulography. The presence of significant
stenosis (50% reduction in vessel diameter compared with
the adjacent segment) was ascertained and quantified by 1 of
the 2 attending radiologists, who were unaware of results of
index tests; therefore, our study can be considered blinded.
The angiogram usually was assessed by only 1 radiologist.
Qa measurements were unobtainable in 4 of 127 subjects
(shown on the Transonic [Transonic System Inc, Ithaca, NY]
device as an unusual curve); thus, these AVFs were not
included in the final analysis. Fistulography showed they all
had early venous collaterals immediately beyond the anasto-
mosis, an anatomic condition that makes it impossible to
cannulate the main trunk of the access and leads to arterial
and venous needles being placed in 2 different noncommuni-
cating branches, making flow measurement impossible be-
cause of lack of recirculation of the saline bolus with
inverted blood tubing. Three AVFs had a normal angiogram,
whereas stenosis was documented in 1 AVF. Fistulography
showed a subclavian stenosis in 3 subjects, and these AVFs
(Qas of 887, 1,016, and 1,176 mL/min) also were excluded
from the final analysis, which therefore was limited to a
cohort of 120 AVFs.
The stenosis-predicting role of changes in Qa over time
was evaluated prospectively in a subpopulation of 42 AVFs.
Because the aim of the study is to identify stenosis, not
evaluate its rate of progression, only AVFs with no stenotic
lesions on the baseline angiogram were included in this part
of the study. Twenty-four of 66 eligible AVFs were lost to
follow-up because of patient death (n 9), kidney transplan-
tation (n  5), transfer to other facilities (n  6), or refusal
of a follow-up angiogram (n  4); therefore, 42 nonstenotic
AVFs for which at least 2 serial Qa measurements and
fistulograms were available were included in the final analy-
sis. During follow-up, Qa was monitored every 2 to 4
months, and fistulography was performed anytime a dQa
greater than 15% was documented or after a median of 16.5
months (10th to 90th percentile, 11.0 to 26.0 months) from
the initial angiogram in AVFs showing no significant change
in Qa. Median follow-up was 12.0 months (10th to 90th
percentile, 7.0 to 26.0 months). During follow-up, 20 AVFs
developed greater than 50% stenosis after a median of 10.0
months (10th to 90th percentile, 5.0 to 20.0 months), whereas
fistulograms showed no changes in the remaining 22 AVFs.
Prediction of thrombosis. The role of index tests and the
presence of stenosis in predicting incipient (ie, within 7
months of the initial angiogram) thrombosis was evaluated
prospectively in a subpopulation of 65 AVFs with an ad-
equate intervention-free follow-up.
Fifty-five of 120 AVFs were excluded from this part of the
study because either they underwent treatment of stenotic
lesions (n  14) or follow-up with a patent access was less
than 12 months because of death (n 15), kidney transplan-
tation (n  6), transfer to another facility (n  6), or end of
follow-up (n 14).
The anastomosis was located at the wrist in 52 AVFs and
midforearm in 13 AVFs. Forty-one AVFs had greater than
50% stenosis.
Serial Qa measurements were available in only 30 AVFs;
thus, the predictive role of dQa for thrombosis could only be
calculated in this subgroup.
Twelve AVFs thrombosed within 7 months of the angio-
gram after a median of 4.0 months (10th to 90th percentile,
2.0 to 7.0 months), and thrombosis rate in the population as a
whole was 0.162 events/AVF-year at risk.
Reproducibility. Evaluation of reproducibility was per-
formed April to July 1998. To minimize hemodynamic
status–dependent intra-assay Qa variability, no antihyperten-
sive medication was administered before dialysis, intradia-
lytic fluid loss was set at a rate no greater than 800 mL/hour,
and Qa measurements were performed in the first 90 minutes
of hemodialysis sessions in stable cardiovascular conditions.
Measurements were not performed if predialysis MAP dif-
fered considerably from the subject’s customary value or
MAP varied during Qa testing by more than 15 mm Hg from
one measurement to another and from the predialysis value.
To ensure interassay reproducibility, Qa measurements were
postponed if predialysis MAP showed differences greater
than 15 mm Hg with respect to previous sessions in which
measurements had been performed.
These conditions were not difficult to meet because only
28 of 390 Qa measurements (7.2%) were postponed because
of intradialytic cardiovascular instability, and 23 of 162
measurements (14.2%), because of predialyis MAP differ-
ences greater than 15 mm Hg in serial Qa measurements.
In addition, position of the needles, evaluated as distance
from the arteriovenous anastomosis, always was recorded to
place the needles in approximately the same position in
subsequent measurements, and Qa measurements were per-
formed in triplicate and by the same operators (N.T., L.G.,
and V.B.).
Access Surveillance
Qa was measured by means of ultrasound dilution tech-
nique using the Transonic HD01 monitor, as described
elsewhere.20 AVFs were cannulated with 15-G needles, and
the arterial needle was placed in the main trunk of the
feeding vein, proximal to any collateral veins and facing the
incoming blood flow. The venous needle always was placed
facing the shoulder, either in the main stream of the access or
one of its branches.
Qa measurements were performed in triplicate within 30
to 90 minutes after starting dialysis and then averaged. Qb
was set at greater than 200 mL/min, and ultrafiltration was
turned off 3 minutes before taking measurements.
Arterial blood pressure was measured using an oscillomet-
ric cuff method immediately after each Qa measurement, Qa
was adjusted for MAP (Qa/MAP), and measurements were
then averaged.
dQa was calculated as follows:
dQa (%) 100  (Qa2  Qa1)/Qa1
where Qa1 is the initial value and Qa2 is the value at the
subsequent measurement, with dQa greater than 0% indicat-
ing that Qa decreased over time. Values less than 0%,
indicating an increase in Qa, were reported as 0%.
Access recirculation was evaluated by means of both Rhd
using the Transonic HD monitor and Ru using the slow-flow
technique.21 Tests were performed within 30 to 60 minutes
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of starting the dialysis treatment. For Ru measurement,
arterial (A) and venous (V) samples were draw at a Qb of
300 to 350 mL/min, and the systemic (S) sample was drawn
from the arterial tubing after reducing Qb to 50 mL/min for
20 to 30 seconds. Blood urea nitrogen concentrations were
measured in all samples, and Ru was calculated as follows:
Ru (%) (S  A)/(S V)  100
Negative arterial prepump pressure and Qb were monitored
during each dialysis session: the negative arterial pressure
alarm was set at 250 mm Hg, and any persistent (ie, in at
least 2 consecutive hemodialysis sessions) decrease in pre-
scribed Qb (dQb, in milliliters per minute) that was needed
to proceed with dialysis because of a high negative arterial
pressure was recorded.
Fistulography
Fistulography was performed before dialysis using the
arterial needle for contrast medium injection. The AVF then
was visualized in its entirety, inverting flow in the venous
limb with an inflated sphygmomanometer. In the few occa-
sions in which it was impossible to visualize the anastomo-
sis, a fistulogram was obtained by puncturing the brachial
artery on a nondialysis day. Images were acquired in at least
2 planes.
Statistical Analyses
Data are reported as percentage, mean  SD, or median
(10th to 90th percentile), unless stated otherwise. Normally
distributed data were analyzed by means of unpaired t-test;
and skewed data, by Mann-Whitney U test.
To identify optimal test and threshold values for predict-
ing stenosis and incipient thrombosis, receiver operating
characteristic (ROC) curve analysis was performed22 by
plotting sensitivity versus false-positive rate (FPR) at differ-
ent cutoff levels of the predictor being tested. Sensitivity is
defined as the percentage of stenotic or thrombosed AVFs
with a positive test result (true-positive [TP] result). Specific-
ity is defined as the percentage of AVFs with no stenosis or
thrombosis with a negative test result (true-negative [TN]
result), and FPR (equal to 1- specificity), as the percentage
of AVFs with no stenosis or thrombosis that tested positive.
The diagnostic efficiency of different test thresholds is
defined as the sum of TP and TN results, ie, the percentage of
AVFs in which test result and diagnosis agree in the popula-
tion as a whole.
Post-test probabilities after a positive (PPP) or negative
test result (PPN) for stenosis and incipient thrombosis also
were calculated for different thresholds of the index tests, as
follows:
PPP (%)  prevalence TP/(prevalence TP)
 ([1  prevalence] FPR)
PPN (%)  prevalence (1  TP)/(prevalence
[1  TP]) ([1  prevalence] TN)
where prevalence is the percentage of AVFs with stenosis or
thrombosis.
We used the coefficient of variation (CV; CV 100 SD/
mean) to describe intra-assay and interassay variability as a
percentage of the average value. Pooled intra-assay and interas-
say SDs and CVs for Qa, MAP, and Qa/MAP also were
calculated using equations described by De Soto et al.23
Significance is set at 2-sided P less than 0.05.
Analyses were conducted using SPSS for Windows, ver-
sion 11.0 software (SPSS Inc, Chicago, IL). ROC curve
analysis was performed using the Astute DDU Software
(The University of Leeds, Leeds, UK).
RESULTS
Characteristics of subjects and AVFs considered
in the final analysis are listed in Tables 1 and 2.
In this unselected group of subjects with fore-
arm AVFs, the prevalence of stenosis was 45.0%
and was similar in both wrist (43 of 91 AVFs;
47.2%) and midforearm AVFs (11 of 29 AVFs;
37.9%). Subjects with stenosis did not differ
from those with normal AVFs in terms of age,
sex distribution, or prevalence of symptomatic
cardiovascular disease, but they had a greater
prevalence of diabetes.
Stenotic AVFs had a significantly greater preva-
lence of access recirculation and dQb.
Qa values are shown in Fig 1. Median Qa was
1,024 mL/min (10th to 90th percentile, 602 to
1,362 mL/min) in normal wrist AVFs, 387 mL/
min (10th to 90th percentile, 137 to 694 mL/min)
in stenotic wrist AVFs, 1,496 mL/min (10th to
90th percentile, 1,016 to 2,390 mL/min) in mid-
forearm normal AVFs, and 573 mL/min (10th to
90th percentile, 310 to 879 mL/min) in stenotic
midforearm AVFs. Stenotic AVFs had signifi-
cantly lower median Qa values than normal
AVFs in both the wrist (P 0.001) and midfore-
arm (P  0.001) groups. Qa levels were signifi-
cantly greater in midforearm than wrist AVFs in
both normal (P  0.001) and stenotic accesses
(P 0.021).
Table 1. Subject Characteristics
Normal AVFs Stenotic AVFs P
No. of subjects 66 54
Age (y) 63  12 61  14 NS
Sex (men/women) 41/25 36/18 NS
Proportion of
diabetes (%) 15.1 31.5 0.048
Proportion of
cardiovascular
disease (%) 36.4 42.6 NS
Abbreviation: NS, not significant.
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Analyses of Variability
Intra-assay CVs were 5.0%  2.7% for Qa,
5.3%  2.8% for MAP, and 6.2%  3.3% for
Qa/MAP (n  108). CVs for Qa and Qa/MAP
differed significantly (P  0.004). Interassay
variability was evaluated in 40 AVFs with dupli-
cate Qa measurements performed a median of
2.0 weeks (10th to 90th percentile, 1.0 to 7.0
weeks) apart; hemodynamic conditions at the
time of testing were similar, shown by a mean
Table 2. AVF Characteristics
Normal AVFs Stenotic AVFs P
No. of AVFs 66 54
AVF age (mo) 11 (2–27) 12 (2–28) NS
AVF anastomosis location (%)
Wrist 73.9 79.6 NS
Midforearm 26.1 20.4 NS
Degree of stenosis (%) 0 (0–30) 78 (65–90) 0.001
Proportion of multiple stenoses (%) — 25.9
Proportion of stenosis 2 cm (%) — 11.1
Location of stenosis (%)
Arterial — 5.5
Venous perianastotic (initial 4 cm) — 81.4
Venous distal (past initial 4 cm) — 13.1
Prevalence of Rhd 0 (%) 1.5 26.9 0.001
Decrease in Qb to continue dialysis (mL/min) 0 (0–10) 40 (23–45) 0.001
Abbreviation: NS, not significant.
Fig 1. Ultrasound dilution
Qas. Open circles, normal
wrist AVF; closed circles,
stenotic wrist AVF; open tri-
angles, normal midforearm
AVF; closed triangles, ste-
notic midforearm AVF. Ste-
notic AVFs had significantly
lower Qas than normal AVFs
in both wrist and midforearm
accesses (P < 0.001). Mid-
forearm AVFs had signifi-
cantly higher Qas than wrist
AVFs in both normal (P <
0.001) and stenotic sub-
groups (P 0.021)
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predialysis MAP difference of 8.1 4.2 mm Hg
between the 2 sessions. Pooled intra-assay and
interassay SDs and CVs were 56.5 mL/min and
7.9% for Qa, 7.85 mm Hg and 8.2% for MAP,
and 0.96 mL/min/mm Hg and 11.2% for Qa/
MAP, respectively. Qa measurement precision
also was evaluated by plotting mean pooled
intra-assay and interassay Qa values against SD,
shown in Fig 2.
Diagnostic Accuracy in Detecting Stenosis
For stenosis, the diagnostic accuracy of Qa
measurements is shown in Fig 3. ROC curve
analysis showed that single Qa measurement,
Qa/MAP, and dQa had very high discriminative
ability with similar areas under the curve (AUCs).
When ROC curve analyses were performed
for Qa and Qa/MAP in the group of 42 AVFs for
which dQa data were available, AUCs for Qa and
Qa/MAP were 0.912  0.047 and 0.916 
0.053, respectively; neither differed significantly
from those obtained in the general population.
The best combinations of sensitivity and FPR
for surrogate markers of low blood flow also are
shown in Fig 3. AUCs for dQb, Ru, and Rhd
were 0.724  0.05, 0.636  0.055, and 0.629 
0.053, respectively; all were significantly lower
than those obtained for Qa, dQa, and Qa/MAP
measurements (P 0.05).
The diagnostic accuracy of stenosis was evalu-
ated for different thresholds of different tests; the
best tests and thresholds in order of efficiency are
listed in Table 3. The most efficient predictor of
stenosis was a single Qa less than 750 mL/min,
either alone or in combination with dQa greater
than 25%. dQa and Qa/MAP did not improve the
diagnostic efficiency of the single Qa measure-
ment, even at their most efficient values of dQa
greater than 20% and Qa/MAP less than 6.5
mL/min/mm Hg.
Including the 3 subjects with subclavian steno-
sis in the analysis led to a slight reduction in
diagnostic accuracy for stenosis. For instance,
Fig 2. Relationship be-
tween pooled intra-assay and
interassay Qa means and SD.
The 2 parameters correlated
significantly (r  0.682; P <
0.001).
Fig 3. ROC curve analysis of Qa measurement as
predictor of stenosis. Best combinations of sensitivity
and FPR for Ru, Rhd, and dQb are included. Dashed
line at 45° indicates no discriminative ability (AUC 
0.5).
TESSITORE ET AL336
the sensitivity of Qa less than 750 mL/min de-
creased from 89.0% to 84.2%, and its efficiency
changed from 90.1% to 87.8%. If the 4 addi-
tional AVFs in which Qa measurements were
unobtainable also are included, there was an
additional decline in diagnostic accuracy, with
efficiency of 85.0%, sensitivity of 82.8%, and
specificity of 87.0%, values still compatible with
an excellent diagnostic performance.
The best diagnostic performances of dQb, Ru,
and Rhd showed efficiency values that make
their clinical utility doubtful.
Because wrist and midforearm AVFs had sig-
nificantly different Qa levels in both normal and
stenotic accesses, we evaluated whether diagnos-
tic criteria for stenosis should be different accord-
ing to location of the anastomosis (Table 4). The
most efficient value for detecting stenosis was
Qa less than 750 mL/min in wrist AVFs and Qa
less than 1,000 mL/min in midforearm AVFs.
Adjusting Qa for MAP did not improve the
diagnostic accuracy of single Qa measurements
in either subgroup. The diagnostic accuracy of
dQa in the 2 subgroups was not calculated given
the limited number of midforearm AVFs with
available data (3 normal and 3 stenotic AVFs).
Diagnostic Accuracy in Predicting Thrombosis
Figure 4 shows the diagnostic accuracy of the
different tests in predicting incipient thrombosis
according to ROC curve analysis. Single Qa
measurement showed the greatest AUC, which
was the same for Qa/MAP (AUC, 0.975 0.016;
data not shown in Fig 4). All the other tests were
less effective, but still acceptable, discrimina-
tors. Figure 4 also shows the sensitivity and FPR
of the presence of anatomic stenosis for incipient
thrombosis; the AUC of 0.726  0.065 was
significantly lower than for Qa (P 0.036).
ROC curves analyses for Qa, Qa/MAP, Ru,
Rhd, dQb, and stenosis were reevaluated in the
group of 30 AVFs with dQa data available: AUCs
were 0.964  0.029 for Qa, 0.947  0.045 for
Qa/MAP, 0.813  0.104 for Ru, 0.702  0.137
for Rhd, 0.782  0.173 for dQb, and 0.711 
0.119 for stenosis. None of these differed signifi-
cantly from those obtained in the general popula-
tion.
Table 5 lists optimal tests and thresholds for
predicting thrombosis in order of efficiency. The
most efficient test was Qa less than 300 mL/min
for both wrist and midforearm AVFs. Qa/MAP
Table 3. Diagnostic Accuracy of Different Tests and Thresholds to Detect Stenosis
Efficiency (%) Sensitivity (%) Specificity (%) PPP (%) PPN (%)
Either Qa750 mL/min or dQa25% 90.4 95.0 86.3 85.2 5.2
Qa750 mL/min 90.1 89.0 90.9 89.0 9.1
Either Qa600 mL/min or dQa25% 88.1 95.0 81.8 82.6 5.3
dQa 20% 88.1 90.0 86.3 85.7 9.5
Qa 900 mL/min 86.6 96.3 78.8 78.8 3.7
Qa 600 mL/min 86.6 75.9 95.4 93.2 17.1
Qa/MAP 6.5 85.5 78.5 91.6 89.2 17.0
Qa 500 mL/min 79.1 55.5 98.4 96.7 27.0
dQb 40 mL/min 76.0 48.0 98.4 96.1 29.7
Rhd 0 66.6 26.9 98.4 93.3 37.3
Ru 3% 64.2 59.1 68.3 60.4 32.8
Table 4. Diagnostic Accuracy of Qa Measurements to Detect Stenosis in Wrist and Midforearm Fistulae
Efficiency (%) Sensitivity (%) Specificity (%) PPP (%) PPN (%)
dAVF pAVF dAVF pAVF dAVF pAVF dAVF pAVF dAVF pAVF
Qa 750 mL/min 90.1 89.6 93.0 72.7 87.5 100 86.9 100 6.7 14.3
Qa 1,000 mL/min 84.6 93.1 97.6 90.9 72.9 94.1 76.3 90.9 2.8 5.6
Qa/MAP 6.5 85.3 82.6 82.7 63.6 89.2 100 86.2 100 15.4 25.0
Qa/MAP 9.5 70.6 86.9 93.1 90.9 51.3 83.3 61.7 83.3 9.6 10.0
Abbreviations: dAVF, wrist AVF; pAVF, midforearm AVF.
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did not improve the diagnostic efficiency of
single Qa measurement; access recirculation mea-
surements and dQb also were good discrimina-
tors, whereas the lowest predictive accuracy was
recorded for dQa and the presence of stenosis.
DISCUSSION
K/DOQI guidelines recommend routine sur-
veillance for hemodynamically significant steno-
sis in both grafts and AVFs because of the evi-
dence that prophylactic stenosis correction
improves access patency rates.1
However, this approach has been questioned
and considered premature because there still are
several unresolved issues concerning the predic-
tive accuracy of the monitoring tools; full risk,
benefit, and cost accounting of the surveillance
program; optimal timing of a corrective interven-
tion; and lack of studies adequate in methods to
address these issues.19
Regarding accuracy in diagnosing stenosis in
AVFs, the few available studies8-10 have method
biases, eg, small sample size,10 combined reports
on grafts and AVFs,10 and no concurrent control
group,8,9 making accurate identification of opti-
mal criteria for detecting stenosis impossible.
Most studies on diagnostic accuracy in predict-
ing thrombosis also have been biased by small
sample size9,12,15 and the reporting of cumulative
data for AVFs and grafts,6,11,12,15,16 and they have
proposed a wide variety of diagnostic criteria. In
addition, the poor reproducibility of Qa measure-
ment4,23 remains a source of major concern for
the clinical applicability of Qa surveillance.
The pooled CV for Qa measurements and the
regression equation between mean Qa values and
their SDs obtained in our study indicate that
assay reproducibility accounts for up to 16% of
Qa measurement variability, even under standard-
ized conditions in which hemodynamic variabil-
ity is minimized. Qa variability was lower in our
study than that reported for grafts,23 but similar
to what others reported in AVFs,4 who found
pooled CVs similar to ours for MAP (7.9%
versus 8.2%), Qa (9.5% versus 7.9%), and
MAP/Qa (11.9% versus 11.2% for Qa/MAP in
our study) in hemodynamically stable subjects
during the first hour of dialysis.
Despite the relatively high variability, Qa mea-
surement shows an excellent diagnostic perfor-
mance in detecting access dysfunction; this find-
ing is explained partially by the high prevalence
of stenosis and thrombosis in our unselected
forearm AVF population, a situation that usually
ensures good performance, even for tests with
less than ideal diagnostic accuracy. ROC curve
analysis showed that Qa measurement by ultra-
Fig 4. ROC curve analysis of Qa, dQa, Ru, Rhd, and
dQb measurements as predictors of incipient thrombo-
sis. Sensitivity and FPR values of the presence of
stenosis are included. Dashed line at 45° indicates no
discriminative ability (AUC 0.5).
Table 5. Diagnostic Accuracy of Different Tests and Thresholds to Predict Thrombosis
Efficiency (%) Sensitivity (%) Specificity (%) PPP (%) PPN (%)
Qa 300 mL/min 93.8 91.6 94.3 78.5 2.0
Qa 350 mL/min 92.3 100 90.5 70.5 0
Qa/MAP 2.5 91.4 75.0 98.0 88.8 5.7
Rhd 2% 90.7 75.0 94.3 75.0 5.7
Ru 5% 87.6 66.6 92.3 66.6 7.7
dQb 60 mL/min 87.6 50.0 92.6 75.0 10.6
dQa 25% 76.7 66.7 77.7 25.0 4.6
Stenosis 55.3 100 45.2 29.2 0
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sound dilution had AUC values greater than 0.90
for detecting stenosis and predicting thrombosis,
indicating that the test would be useful in clinical
practice. For the diagnosis of stenosis, Qa values
ranging from less than 600 mL/min to less than
900 mL/min showed an excellent combination of
sensitivity and specificity, with efficiency greater
than 85%.
Neither Qa/MAP nor dQa, even at their best
thresholds of Qa/MAP less than 6.5 and dQa
greater than 20%, improved the performance of
absolute Qa measurement, as reported by others
for dQa as a predictor of stenosis in AVFs9 and
dQa and Qa/MAP as predictors of thrombosis in
grafts.24,25
Conversely, combining Qa with dQa proved
capable of providing additional improvement in
diagnostic accuracy. The greatest efficiency value
was obtained for the either/or combination of Qa
less than 750 mL/min and dQa greater than 25%,
which improved sensitivity without a substantial
increase in FPR compared with Qa less than 750
mL/min. The combination is preferable to single
Qa measurements because recent reports show-
ing that early identification and correction of
stenosis improve AVF survival10,26,27 favor tests
with the greatest sensitivity, even at the cost of an
increase in number of unnecessary diagnostic
procedures.
Our results show that criteria proposed by
K/DOQI guidelines for referral for angiography
also are highly accurate for forearm AVFs, al-
though a greater Qa threshold than the Qa less
than 600 mL/min proposed by K/DOQI may be
more appropriate. They also favor implementing
surveillance programs based on regular serial Qa
measurements, although the improvement in sen-
sitivity should be weighed against the greater
costs of surveillance and greater workload for
the dialysis staff.
We confirm that the threshold of Qa less than
500 mL/min, recently proposed as the best crite-
rion for detecting stenosis in AVFs,9 has a high
predictive value of a positive test, but this thresh-
old had such low efficiency and sensitivity rat-
ings that its clinical value is questionable be-
cause it is unable to identify a large number of
AVFs that may benefit from stenosis correction.
Instead, when a surveillance program based on
frequent serial Qa measurements is unfeasible, a
threshold of Qa less than 900 mL/min should be
used as the indication for fistulography given its
high sensitivity (96%) and acceptable FPR (21%).
Our study also shows that location of the
arteriovenous anastomosis in forearm AVFs is an
important determinant of Qa levels because both
normal and stenotic midforearm AVFs had greater
Qa values than wrist AVFs. This probably is the
result of a greater arterial vasodilatory response
to the construction of the anastomosis as a conse-
quence of the greater arterial diameter and less
pronounced atherosclerotic wall lesions and cal-
cification of more proximal vessels.28
As expected, optimal Qa and Qa/MAP thresh-
old levels for stenosis were greater in midfore-
arm than wrist AVFs. Unfortunately, the small
number of midforearm AVFs with serial Qa mea-
surements and fistulograms made it impossible
for us to compare the diagnostic role of dQa in
the 2 subgroups.
That Qa/MAP should offer no advantage over
Qa in terms of diagnostic accuracy for stenosis
(and thrombosis) may be interpreted as sugges-
tive of a limited role of changes in MAP on Qa
levels in fistulae, but it more likely is caused by
our study protocol, in which MAP variation was
minimized by taking Qa measurements in the
first 90 minutes of dialysis in sessions with stable
cardiovascular conditions. As long as Qa mea-
surements are performed under standardized con-
ditions and in dialysis sessions with reproducible
hemodynamic status, adjustment of Qa for MAP
is not worthwhile because the increase in com-
plexity of surveillance does not benefit diagnos-
tic performance.
Surrogate markers of Qa, such as Qb monitor-
ing and access recirculation measurement, offer
no advantage over Qa measurement in terms of
detecting stenosis and are of uncertain clinical
utility because of their low sensitivity.
Qa measurement also proved to be the best
marker of incipient thrombosis in AVFs. The best
thresholds were between Qa less than 300 mL/
min and Qa less than 350 mL/min, the former
showing the best efficiency, and the latter, the
best absolute sensitivity and acceptable FPR.
Thresholds identified by our study are similar to
those proposed by the largest published study
that identified duplex ultrasound Qa less than
400 mL/min as the best predictor of thrombosis
in AVFs.17
Measuring access recirculation also proved to
Qa AND AVF DYSFUNCTION 339
be a good predictor of incipient thrombosis in
AVFs; the most efficient values were Rhd greater
than 2% and Ru greater than 5%, but the lower
sensitivity makes this test less useful than Qa
surveillance.
The near-perfect predictive power for thrombo-
sis shown by Qa and the excellent diagnostic
performance by access recirculation should be
considered with caution because our study may
overestimate predictive accuracy because of the
relatively small sample size, prolonged observa-
tion period, and unintentional selection bias asso-
ciated with subgroup analysis. However, our
data indicate that detecting Qa less than 350
mL/min and/or the presence of access recircula-
tion should prompt for immediate action in AVFs
to prevent thrombosis.
dQa proved less accurate in predicting throm-
bosis than single Qa measurement, supporting
the notion that a decrease in flow over time better
reflects a developing process, such as stenosis,
whereas absolute Qa levels are related to patency
in AVFs.29 However, this part of the study may
be underpowered for an accurate evaluation of
the role of dQa in predicting thrombosis, and
larger prospective trials obviously are needed.
Our study shows that identifying anatomic
stenosis in AVFs is less effective than evaluating
functional and/or hemodynamic parameters to
pinpoint an access at risk for incipient failure.
The presence of stenosis has a poor predictive
value for future short-term episodes of thrombo-
sis, thus confirming the observation that a ste-
notic AVF can remain patent for a long time,1 but
also indicating that patency depends on Qa levels
being greater than a critical threshold of 300 to
350 mL/min. Our study also indicates that nonste-
notic AVFs virtually never clot, confirming previ-
ous reports that stenosis almost invariably under-
lies a thrombotic event in AVFs.30
In predicting both stenosis and thrombosis, Qa
showed greater AUC values than those reported
for grafts,31 suggesting that Qa measurement is
better suited to predict dysfunction in AVFs than
grafts. This discrepancy may be explained by the
different locations of stenosis in the accesses,
being largely perianastomotic (inflow) in AVFs
and usually located in the draining vein (outflow)
in grafts, because it has been shown that high
inflow resistance has a more profound effect on
total access resistance, and thus on Qa, than high
outflow resistance.32
Our study also shows that ultrasound dilution
Qa measurements are feasible in the vast major-
ity of forearm AVFs and suggests that if Qa is
unobtainable, fistulography and/or duplex ultra-
sound evaluation of the access is warranted. It
also suggests that Qa monitoring is inaccurate in
detecting subclavian stenosis, which may be iden-
tified better by other means, eg, an increase in
dialysis venous pressure and/or arm swelling.
Finally, the study provides information on the
optimal frequency of Qa surveillance in AVFs:
the median time to develop stenosis and thrombo-
sis observed in our prospective trial suggests that
a surveillance program based on quarterly/
bimonthly Qa measurement should be cost-
effective in detecting AVFs at risk.
In conclusion, our study shows that ultrasound
dilution Qa measurement is a sufficiently repro-
ducible and highly accurate technique to detect
stenosis and predict thrombosis in native mature
forearm AVFs. For stenosis, diagnostic accuracy
of single Qa measurement is not improved by
adjusting for MAP or dQa, whereas combining
Qa and dQa improves sensitivity, justifying sur-
veillance programs based on serial Qa measure-
ments. In the group of AVFs as a whole, optimal
criteria for stenosis were Qa less than 750 mL/
min and its either/or combination with dQa
greater than 25%, the latter preferable to the
former because it induces a slight increase in
sensitivity. However, the optimal threshold for
stenosis varies according to arteriovenous anasto-
mosis location, being higher for the more proxi-
mal forearm AVFs (Qa  1,000 mL/min in
midforearm AVFs versus Qa  750 mL/min in
wrist AVFs). Single Qa measurement also proved
to be a highly accurate predictor of incipient
thrombosis in forearm AVFs; the ideal threshold
was between less than 300 and less than 350
mL/min. Qa/MAP and dQA impaired, rather than
improved, single Qa diagnostic performance,
whereas access recirculation and dQb showed
good predictive power for thrombosis, although
they were inferior to Qa because of their lower
sensitivity.
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